Healthcare capital Petrichor specializes in healthcare-focused growth capital and long-duration flexible mandates, indicating a clear opportunity to cross-sell tailored investment structures to healthcare firms seeking scalable financing and strategic guidance.

Recent portfolio growth Active investments in Vero Biotech, Ascend Gctx, Fennec Pharmaceuticals, Aurion Biotech, and Leukocare demonstrate a track record of supporting late-stage and growth-stage healthcare companies, suggesting potential for co-investments, follow-on funding, or partnership deals with similar firms.

Strategic partnerships Petrichor’s collaboration with big-name investors and funds (DCVC Bio, Deerfield, Abingworth, etc.) signals strong syndication capabilities and value-add through networks, offering a pathway to introduce prospective portfolio companies and co-investment opportunities.

Global and cross-structure The firm emphasizes execution across sectors, geographies, and capital structures, implying readiness to engage with healthcare companies pursuing international expansion, complex financing, or bespoke structures that align with their growth plans.

Growth-stage focus With a revenue profile in the tens of millions and a history of financing rounds for growth-oriented healthcare companies, Petrichor is positioned to target mid to late-stage opportunities, venture-to-growth transitions, and strategic exits for potential clients or partner firms.